Key Takeaways from COMPAMED 2025

COMPAMED likes to describe itself as the leading marketplace for medical manufacturing suppliers, and microtechnology now sits at the center of that story. The COMPAMED HIGH-TECH FORUM in Hall 8a is explicitly focused on microtechnology, nanotechnology, photonics and new materials for miniaturized systems.

On the floor, that translated into a very specific visual:

• Microfluidic chips that turn sample prep, reaction and detection into a postage-stamp sized package.

• Micro pumps and valves that are meant to disappear inside wearable patches or compact instruments.

• Ultra-fine wires and tubes, micro connectors and tiny optical assemblies aimed at catheters, endoscopes and implants.

Official COMPAMED coverage makes the same point. Micromanufacturing, it argues, delivers high precision with minimal space and mass and enables “maximum effects in the smallest spaces” for implants, surgical tools and diagnostic cartridges.

For tubing and elastomer suppliers, the implication is simple and slightly uncomfortable. If you ship peristaltic pump tubing, catheter liners or molded seals into these systems, you are in the microtechnology business whether you call it that or not. Wall thickness, concentricity, surface finish and bondability are no longer housekeeping details. They determine whether a pump self-primes, whether an optical sensor sees through a tube wall, whether a valve leaks or not after sterilization.

We saw more interest in:

• Transparent TPE and silicone formulations that stay clear enough for in-line sensing.

• Materials that can hold burst and kink performance even as walls get thinner.

• Polymers that tolerate laser drilling, welding or marking without damaging a neighboring circuit board.

Device teams are moving fast into “small and smart.” Component partners that cannot follow on tolerances, surfaces and integration will feel bigger than they look.

Materials in the squeeze: performance, regulation, carbon

Materials have always been a major reason to visit COMPAMED. The fair and its magazine routinely highlight “innovative materials” and advanced composites alongside microtechnology as one of the key hot topics in medical production.

This year, the material conversation felt less like a search for the next exotic polymer and more like managing a three-way squeeze:

• Higher performance expectations, especially for implants and long-life components.

• Regulatory pressure, including PFAS scrutiny and broader chemicals policy trends.

• Carbon and waste targets that are starting to reach all the way down into bill-of-materials decisions.

The COMPAMED Innovation Forum highlighted smart implant technologies and described how miniaturization and “intelligent” functions are raising the bar for polymer implants, coatings and encapsulants in pacemakers, orthopedic systems and neurological devices. That thinking carried through the show, with more talk of fatigue life, surface modification and long-term stability in difficult environments.

At the same time, official COMPAMED content and exhibitor material pointed to biocompatible plastics, advanced coating systems and composite structures that aim to improve device life cycle and environmental footprint while reducing reliance on chemistries that may face future restriction. PFAS and fluorinated additives sit squarely in that spotlight.

For fluid paths and molded components, that creates a set of very practical questions:

• If a tubing or liner solution depends on a fluoropolymer, what is the plan if restrictions tighten in a key region.

• When a peristaltic pump set is disposed by incineration at scale, what are we really burning and what does that mean for carbon reporting.

• Can we simplify a device by moving from multi-material assemblies to fewer, smarter materials without giving up fatigue or burst performance.

On a COMPAMED aisle, it is easy to appreciate a “PFAS free” label or a “bio-based content” badge on a sample board. In an engineering review six months later, the trade-offs are less pretty: friction coefficients, torque, permeability, price. The suppliers who stand out will be the ones who can walk customers through those trade-offs honestly, with test data and long-term roadmaps, not just a green icon.

Time to market is now for sale

COMPAMED is no longer just a place to shop for parts. It is also where test labs, notified bodies and contract manufacturers show how they can remove months from a device program.

Press information around MEDICA and COMPAMED calls out AI, robotics and automation, digitally networked care and market development as central topics, and notes that service providers use the fair to present integrated development, testing and certification packages. TÜV SÜD, as one visible example, positions its presence on “optimizing time to market” for IVD and medical devices through combined regulatory and laboratory support.

On the show floor, “one-stop” offers are everywhere:

• Contract manufacturers promising support from design for manufacturability through process validation and documentation that matches MDR and FDA expectations.

• Test labs bundling biocompatibility, electrical safety, software validation, cybersecurity and packaging into single programs instead of separate projects.

• Automation and digitalization vendors selling in-line inspection, data capture and digital work instructions as ways to shorten validations and make changes less painful.

There is a tension here that is worth admitting. Many stands promise “from idea to approval,” but even the best program still involves several partners, overlapping responsibilities and handoffs that need real project management. Buying three one-stop shops does not magically remove bottlenecks.

Where materials and components matter is in how much friction they add or remove.

A tubing family with a clear and complete data package simplifies test plans. A stable global supply position avoids emergency revalidations when a plant or resin changes. An extrusion or molding process that is already validated to the right cleanliness level can be slotted into a larger line without starting from zero.

Time to market is still a shared problem, but it is no longer only the OEM’s problem. At COMPAMED, it is clearly something suppliers believe they can influence and, increasingly, something they are expected to influence.

Sustainability is not new in the COMPAMED program. The difference in 2025 is how visible it has become on the stands themselves.

Across the halls, more exhibitors led with sustainability claims and third-party ratings at the front of the booth rather than at the back of the slide deck. EcoVadis is one of the clearest markers. The platform evaluates companies on environment, labor and human rights, ethics and sustainable procurement and awards Bronze, Silver, Gold and Platinum medals based on performance.

For many hospitals, pharma companies and medtech OEMs, EcoVadis and similar tools now feed directly into supplier qualification processes. Sector initiatives such as the Responsible Health Initiative use common assessments to streamline ESG due diligence across buyers and to create a shared language on supplier performance.

At COMPAMED, the result is easy to spot. Medals are printed on booth graphics. ESG one-pagers sit next to process diagrams. Conversations about Scope 3 emissions, renewable energy at plants and supplier codes of conduct have moved from hallway sidebars to scheduled meetings. The EcoVadis medal is quietly becoming a second logo.

There is a second tension here. It is much easier to print a medal on a wall than to change a resin, a coating or a multi-site manufacturing network. For fluid paths and elastomer parts, material changes trigger extractables testing, device verification and, often, new regulatory filings. That is one reason sustainability roadmaps can lag behind sustainability messaging.

For buyers, that distinction matters. A clear and improving sustainability scorecard is now a basic expectation. The more interesting question is how that scorecard connects back to the actual bill of materials, energy profile and waste streams of the products on the table.

COMPAMED 2025 did not change the fundamentals of medtech manufacturing. It did, however, make the next set of expectations very visible. Micro parts are becoming the norm. Material choices are being tested against regulation and carbon, not just performance. Time to market and sustainability have become things you can buy from the supply base, not only manage internally.

For companies in materials, tubing and fluid paths, that means a good part is now the entry ticket, not the differentiator. The differentiator is the story wrapped around it: how that part enables micro-scale designs, how it behaves under stricter regulatory and ESG scrutiny, how it helps programs move faster and how it fits into a credible sustainability narrative that buyers can take back to their own stakeholders.

COMPAMED made it clear that this story is already being written. The real question for each supplier is how far they are from being able to tell it with a straight face.